Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail SkepticismETF Trends · Oct 12, 2026
Financial Comparison: Crinetics Pharmaceuticals (NASDAQ:CRNX) and Lyra Therapeutics (OTCMKTS:LYRA)Defense World · Sep 21, 2026
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?Fool - Investing News · Sep 10, 2026
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership TeamBusiness Wire · Sep 1, 2026
BlackRock Inc. Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNXDefense World · Aug 26, 2026
AWM Investment Company Inc. Invests $3.18 Million in Crinetics Pharmaceuticals, Inc. $CRNXDefense World · Aug 26, 2026Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$1.18 | -$1.14 | Beat |
| May 7, 2026 | -$1.22 | -$1.23 | Miss |
| Feb 26, 2026 | -$1.37 | -$1.29 | Beat |
| Nov 6, 2025 | -$1.27 | -$1.38 | Miss |
| Aug 7, 2025 | -$1.13 | -$1.23 | Miss |
| May 8, 2025 | -$0.99 | -$1.04 | Miss |